21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

Is histone H2B deubiquitylation via ATXN7L3-dependent enzymes a new mechanism disrupted in neurodevelopmental disorders?

Abhinav Anand, Francisco Bustos

Neurogenetics · 2026

Abstract originale

Neurodevelopmental disorders are lifelong debilitating conditions that affect cognition and originate during embryonic development. Being heterogeneous and with a variety of etiologies, most of these disorders have no targeted treatment or cures, due to our lack of knowledge on the underlying molecular mechanisms disrupted in their pathogenesis. An emerging epigenetic mechanism recently associated with neurodevelopmental disorders is ubiquitylation of histone H2B. This posttranslational modification controls gene expression during neurodevelopment, where histone H2B ubiquitylation levels are tightly regulated by multiple deubiquitylase protein complexes ensuring correct gene expression. Components of deubiquitylase complexes regulating histone H2B ubiquitylation are the protein scaffolds ATXN7L3 and ENY2, and the deubiquitylating enzymes USP22, USP27X, and USP51. Recent clinical studies have highlighted a potential role of H2B ubiquitylation in human neurodevelopment, including the identification of neurodevelopmental disorders associated with gene variants in the ATXN7L3, USP27X and USP51 genes. Here, we summarize our knowledge of the functions of deubiquitylase complexes that regulate histone H2B ubiquitylation and their components in neurodevelopment, and describe ATXN7L3, USP27X, and USP51-associated disorders, proposing future directions on the required research on their fundamental biology that could lead to targeted therapies.

Parole chiave

HumansNeurodevelopmental DisordersHistonesUbiquitinationAnimalsNerve Tissue ProteinsNeurodevelopmentUbiquitin ThiolesteraseTranscription FactorsATXN7L3DeubiquitylasesHistone H2BUSP27XUbiquitin
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Is histone H2B deubiquitylation via ATXN7L3-dependent enzymes a new mechanism disrupted in neurodevelopmental disorders?

Neurodevelopmental disorders are lifelong debilitating conditions that affect cognition and originate during embryonic development. Being heterogeneous and with a variety of etiologies, most of these disorders have no targeted treatment or cures, due to our lack of knowledge on the underlying molecular mechanisms disrupted in their pathogenesis. An emerging epigenetic mechanism recently associated with neurodevelopmental disorders is ubiquitylation of histone H2B. This posttranslational modification controls gene expression during neurodevelopment, where histone H2B ubiquitylation levels are tightly regulated by multiple deubiquitylase protein complexes ensuring correct gene expression. Components of deubiquitylase complexes regulating histone H2B ubiquitylation are the protein scaffolds ATXN7L3 and ENY2, and the deubiquitylating enzymes USP22, USP27X, and USP51. Recent clinical studies have highlighted a potential role of H2B ubiquitylation in human neurodevelopment, including the identification of neurodevelopmental disorders associated with gene variants in the ATXN7L3, USP27X and USP51 genes. Here, we summarize our knowledge of the functions of deubiquitylase complexes that regulate histone H2B ubiquitylation and their components in neurodevelopment, and describe ATXN7L3, USP27X, and USP51-associated disorders, proposing future directions on the required research on their fundamental biology that could lead to targeted therapies.

Introduction

Neurodevelopmental disorders are a heterogeneous group of neurological conditions [1, 2]. On average, 2–3% of the population is affected by neurodevelopmental disorders [3, 4]. With no cure and current treatments prioritizing symptom mitigation, patients who are affected by this debilitating disease experience diminished cognition and adaptive function that begins from infancy and lasts for a lifetime [5]. These predicaments motivate ongoing investigation into the molecular mechanisms behind neurodevelopmental disorders to potentially shed light on novel therapeutic targets.

The ubiquitin system plays key roles in protein biology. This system regulates proteostasis, localization, and interaction regulating crucial cellular processes such as transcription, autophagy, cell cycle, and differentiation [6]. Ubiquitylation refers to the post-translational modification (PTM) of protein substrates via a three-step enzymatic process; leading to the addition of a ubiquitin motif – a 76-amino acid protein added to lysine residues within target proteins [7, 8]. The three steps of ubiquitin addition are activation, conjugation, and ligation, mediated by E1, E2, and E3 enzyme families respectively [9]. Just as ubiquitin can be added, so can it be removed. This action is mediated by the deubiquitylase (DUB) class of enzymes, the largest family of which are the ubiquitin-specific proteases (USPs) [10]. Prior literature demonstrates that neurodevelopmental disorders are frequently associated with genetic perturbations to DUBs [11]. Symptoms vary widely depending on the downstream protein substrates but can range from developmental delay and intellectual disability to craniofacial features, seizures, hypotonia, and congenital abnormalities [12–15]. From a biochemical perspective, however, little is known about the effect of these DUB variants on structural form and biological function.

A critical and highly conserved ubiquitylation process modifies histone H2B (H2Bub1) at lysine 120 (K120) with a single ubiquitin moiety in a dynamic process that helps to govern transcription initiation [16–21]. The E3 ligases RNF20 and RNF40 catalyze histone H2B ubiquitylation [22–27]. Addition of ubiquitin to H2B generally promotes gene expression through chromatin remodeling via Histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 79 dimethylation (H3K79me2) by COMPASS (Complex of Proteins Associated with Set1) and DOT1L respectively in gene bodies, thereby promoting transcription and gene elongation courtesy of stimulated RNA polymerase II processivity via FACT (facilitates chromatin transcription) complex recruitment. The FACT complex then causes conformational changes in nucleosome structure to permit RNA polymerase II to bypass the chromatin barrier [28–31]. However, H2B ubiquitylation can also repress gene expression at quiescent promoters via stabilization of the nucleosome and subsequent inhibition of transcript initiation complex formation [31].

Conversely, The Spt-Ada-Gcn5 acetyltransferase (SAGA) is a transcriptional activator complex that catalyzes H2Bub1 deubiquitylation via its DUB module consisting of ataxin 7 like 3 (ATXN7L3), USP22, and enhancer of yellow 2 transcription factor homolog (ENY2). Another protein, ataxin 7 (ATXN7), connects the DUB module to the overall SAGA complex. The proper SAGA subunit assembly and organization are critical for its efficacious DUB activity [18, 21, 32–40]. Besides USP22, USP27X and USP51 constitute alternative ATXN7L3-dependent DUB complexes that control H2Bub1 deubiquitylation and gene expression [41] (Fig. 1). These complexes broadly regulate H2Bub1 across the genome, mediating the majority of H2Bub1 turnover at actively transcribing genes. Consistently, their disruption drives genome-wide increase in H2Bub1 levels [41]. Although DUB complexes containing USP3, USP7, USP12, or USP46 can also catalyze H2Bub1 deubiquitylation, they regulate more restricted, context dependent transcriptional programs [42–46]. Therefore, active transcription depends on tightly regulated H2Bub1 turnover rather than a continuous ubiquitylated state.

Recent research highlights familial USP27X and USP51 gene variants as well as de novo ATXN7L3 gene variants associated with neurodevelopmental disorders, and new research describes variants via their clinical and biochemical characteristics of disease manifestation. X-linked intellectual disorder 105 (XLID 105), is associated with variants in the USP27X gene and presents as a syndrome with a wide range of symptoms – from intellectual disability to speech delay, autistic behaviors, dysmorphic features, and microcephaly [12, 47]. On the other hand, clinical manifestations of Harel-Tora neurodevelopmental syndrome, associated with ATXN7L3 variants, also vary widely depending on variant. Some symptoms include, but are not limited to: Abnormal head size, global developmental delay, congenital cardiac defects, and dysmorphic features [48]. However, due to the relative recency in investigating USP27X, USP51 and ATXN7L3 variants’ pathogenesis, it is still not clear whether and how they are causative for some or all these symptoms.

Due to the nature of ATXN7L3-dependent DUB complexes as a mechanistically related network that accounts for most H2Bub1 regulation across the genome, this review intends to disclose what is currently known about their components such as ATXN7L3, USP22, USP27X, and USP51, their role in neurodevelopment, descriptions of noteworthy USP27X, USP51 and ATXN7L3 associated disorders, and hypotheses on how these complexes may be a potential therapeutic target for those afflicted with gene variants of their subcomponents. In doing so, further investigation into the role of ATXN7L3-dependent DUBs on developmental regulation via H2B deubiquitination may contribute to a better understanding of their antithetic E3 ligase counterparts’ role as well and reinforce the hypothesis that comprehensive developmental homeostasis is achieved through a dynamic and oscillatory relationship between the two components of the ubiquitin cascade.

The discovery and characterization of USP27X and USP51 as ATXN7L3-dependent DUB complex components

As mentioned above, it was well established that the SAGA DUB module was comprised of ATXN7L3, ENY2 and USP22 forming a complex that catalyzed H2Bub1 deubiquitylation [38]. The idea that additional DUB complexes could deubiquitylate H2Bub1 emerged from seminal experiments by Atanassov and colleagues. They unexpectedly found that loss of USP22 was dispensable for H2Bub1 deubiquitylation although ATXN7L3 was fully required. This suggested that USP22 was not the only interactor partner for ATXN7L3 and ENY2. The existence of additional DUB complexes using alternative DUBs (USP27X and USP51) was discovered through mass spectrometry of purified ATXN7L3, confirming the presence of the non-SAGA components USP27X and USP51. Additionally, overexpression of each of the DUBs resulted in significant reduction of H2Bub1 levels [41]. USP27X and USP51 share significant homology to USP22, with USP27X sharing 82% and USP51 sharing 70%. In addition to the presence of a catalytic domain homologous to USP22 and DUB activity towards H2Bub1, both USP27X and USP51 possess a homologous N-terminal Znf-UBP domain [41], for which USP22 [41] has been demonstrated to be important for interaction with ATXN7L3 and ENY2 [39]. USP27X is unique in that it begins translation from a non-canonical CTG start codon. Evidence for this came from immunoblots in a variety of cell types illustrating a 72 kDa protein as opposed to the documented 50 kDa on databases such as NCBI GenBank [41, 49]. Additional experiments with a mutated CTG codon yielded no endogenous USP27X presence altogether [41].

Using in vitro and in cell experiments, Atanassov and colleagues demonstrated that USP27X and USP51 deubiquitylate H2Bub1 and require ATXN7L3-ENY2 to achieve complete catalytic activity, suggesting that this complex allosterically regulates DUB activity. While USP27X and USP51 do not complex with the SAGA as USP22 does, they do form smaller complexes with ATXN7L3 and ENY2 (Fig. 1). Importantly, USP27X and USP51 compete with USP22 for binding with ATXN7L3 and ENY2, which regulates transcription of particular sets of genes and biological processes related to cell proliferation and tumor growth [41]. Gene specificity could be the result of altered epigenetic marks and subsequent chromatin remodeling juxtapose to target genes. However, this remains speculation, as the exact molecular mechanisms governing protein complex specificity and subsequent histone substrate specificity are currently unknown.

Roles of ATXN7L3-dependent DUB complex components on neurodevelopment

Many developmental processes are controlled by correct histone H2Bub1 levels [16, 17]. It has been shown that SAGA plays a role in neurodevelopment [33]. Additionally, a study by Liang et al. demonstrated that RNF20 loss-of-function results in impaired astrocytic differentiation from neuronal precursors, accompanied by a reduction in H2Bub1 levels. Further experiments highlighted the regulatory intermediary in this relationship was the complexing of RNF20 with the acetyltransferase MOF to activate Stat3 transcription [50]. Furthermore, Schwann cell-specific RNF40 deletion in mice resulted in dysfunctional myelination driving a neuropathy phenotype with axonal degeneration. RNF40 was shown to be recruited to Egr2 target genes to specifically regulate myelination-related gene expression programs [51]. Together, these data suggest that H2B ubiquitylation plays integral roles in the proper development, regulation, and differentiation of neuronal precursors into glial cell subtypes as well as maintain overall nervous system health.

Given the importance of H2B ubiquitylation, it follows that deubiquitylation of histone H2B should offer complementary importance to RNF20/40 ubiquitylation. However, little is known about the roles of deubiquitylases —especially the ATXN7L3-dependent DUB complex components —in nervous system development, as loss of USP22, ENY2, or ATXN7L3 is embryonic lethal in mouse models [52–54] making in vivo studies difficult. Alternatively, we instead summarize the current knowledge on the role these ATXN7L3-dependent DUBs play in neural differentiation and development in vitro.

USP22 and USP27X may influence proper neuronal differentiation

The role of USP22 and USP27X in mouse brain development was addressed by Kobayashi and colleagues [55]. Within the ventricular zone (VZ) and sub-ventricular zone (SVZ) of the developing mammalian brain are populations of neural stem cells and intermediate progenitors respectively that contribute to the development of the cerebral cortex. Kobayashi and colleagues used in utero electroporation of embryonic brains to assess neural progenitor migration patterns under USP22 or USP27X loss of function or overexpression conditions respectively. They found that loss of USP22 led to increases in neural progenitors in the intermediate zone and cortical plate and decreases in the presence of these cells in the VZ and SVZ after two days post electroporation. USP27X overexpression, however, led to a decrease in the number of neural progenitors in the intermediate zone and cortical plate while their numbers in the VZ and SVZ remained unchanged. These data suggest that while USP22 presence promotes differentiation, migration, and repopulation of VZ and SVZ neural progenitors, specific levels of USP27X governed whether neural progenitors underwent proliferation, migration, or differentiation within the developing brain [55]. It is worth mentioning that this study did not formally demonstrate the fidelity of USP22 knockdown or USP27X overexpression in the brain tissue analyzed, determine the expression of endogenous USP22 or USP27X proteins in the developing brain, nor investigate which cell types express these proteins. Furthermore, this study also did not assess if the observed phenotypes were due to changes in H2Bub1 regulation by USP22 or USP27X complexes. Therefore, the presence of endogenous USP22 and USP27X proteins in the developing cortex, and the mechanisms behind these results are yet to be defined.

USP22 regulates neurogenesis upon brain injury

Neurogenesis occurs in the SVZ and dentate gyrus (DG) of the hippocampus in the adult mouse brain. The role of USP22 in this process upon brain injury was investigated by Zhang and colleagues. Using a traumatic brain injury (TBI) model in which direct force was applied to the exposed mouse brain, this group found that USP22 levels decreased one day post-TBI but increased three and five days post-TBI. Furthermore, USP22 is required for neurogenic and migration potential as demonstrated in neurosphere formation assays of neural stem cells obtained from mice post-TBI under USP22 loss or gain of function conditions. Consistently, USP22 knockdown mice show impaired performance in the Morris water maze test performed after TBI, indicating a requirement of USP22 for proper cognitive function upon brain injury. Together, these data reinforce USP22’s role in neurogenesis and cognitive function [56]. Yet again, these studies did not assess if regulation of H2Bub1 by USP22 or other mechanisms explained the phenotypes observed.

USP22 regulates embryonic stem cell differentiation via H2Bub1 deubiquitylation at the SOX2 promoter

The core factors governing embryonic stem cells (ESCs)’ pluripotent state include but are not limited to SOX2, OCT4, and NANOG [57, 58]. Sussman and team showed that USP22 repressed Sox2 transcription via H2Bub1 deubiquitylation at the Sox2 locus. During ESC differentiation via retinoic acid, USP22 levels increased while SOX2 levels decreased. This inverse correlation was observed not only for mouse ESCs, but for human as well – suggestive of a critical regulatory mechanism conserved across species. USP22 knockdown resulted in an increase in Sox2 mRNA while USP22 overexpression resulted in Sox2 downregulation. In fact, the relationship between USP22 protein levels and Sox2 mRNA levels is deliberate, as the mRNA levels of other critical factors NANOG and OCT4 were not significantly downregulated by USP22 – with NANOG only being increased upon SOX2 reduction – nor was the H2Bub1 pattern altered within the Oct4 gene locus [59]. Together, these data suggest the critical conserved role that DUBs such as USP22 and their orthologs play for epigenetic regulation of cell phenotypes. While these experiments indicate that USP22 regulates Sox2 transcription during pluripotency exit, given the heterogeneity of the differentiation protocols used, we cannot conclude that this mechanism occurs in neural cells. Whether the aforementioned dynamic between USP22 and Sox2 persists during neuronal differentiation would be clarified by confirming these findings using neural stem cell to neuron differentiation or directed differentiation models such as iPSC-derived NGN2-induced neurons. Thus, the role of USP22 activity on gene regulation via H2Bub1 deubiquitylation remains understudied from a neurodevelopmental context and represents a potential avenue of research to uncover novel molecular mechanisms impacting neuronal differentiation lineages.

ATXN7L3-dependent DUB complex components are mutated in neurodevelopmental disorders

Consistent with the importance of H2Bub1 in transcriptional regulation, recent studies have linked genetic disruption of ATXN7L3-dependent DUB complex components to neurodevelopmental disorders. Below, we summarize the main findings, implications and limitations of recent reports of gene variants in components of ATXN7L3-dependent DUB complexes that are associated with neurodevelopmental disorders.

Disruptive USP27X variants are associated with X-linked intellectual disorder 105

X-linked intellectual disorder 105 (XLID 105) was annotated in the Mendelian Inheritance of Man database from a report of two families with patients presenting with intellectual disability and other symptoms (OMIM #300984). Within an unbiased study – aimed to the discovery of several new XLID-associated genes, it was found that these patients carried variants in the USP27X gene [12]. The phenotypic spectrum and potential underlying mechanisms of XLID 105 were expanded by Koch and colleagues. They described nine additional families with eight novel inherited gene variants in the USP27X gene. Primarily affecting biological males (with sex chromosomes XY), these patients presented with a wide range of symptoms such as speech delay, intellectual disability, ADHD-related behaviors, dysmorphic features, autistic behaviors, motor delay, ocular abnormalities, or anxiety (Fig. 2). The variants p.Gln36Ter and p.Glu132Ter were predicted to produce USP27X loss of function, and the missense variants p.Gly76Ser, p.Tyr144Cys, p.Lys181Glu, p.Phe313Val, p.Ser404Asn, and p.Tyr381His were of particular interest as these patients presented similar phenotypes as the ones carrying loss of function variants [47].

Through ESC transfections and cycloheximide chase assays, it was found that the missense variants of USP27X did not alter the localization pattern or stability of the USP27X protein. Instead, catalytic activity was greatly reduced in variants p.Gly76Ser, p.Tyr144Cys, p.Phe313Val, p.Tyr381His, and p.Ser404Asn as indicated through K48 and K63 diubiquitin cleavage assays. This reduction in catalytic efficacy was inferred to be the basis of USP27X’s pathogenicity in XLID 105. Further mechanistic details of these defects were obtained using DUB activity-based probes, which label the nucleophilic attack involved in DUB catalysis [60, 61]. However, variants in a region of the protein that was solvent-exposed and not buried within the USP domain structure, such as p.Ser404Asn revealed something unexpected. This variant was still able to disrupt USP27X catalytic activity, leading to the hypothesis that allosteric recognition as well as direct ubiquitin binding by the USP domain contributes to the full DUB capability of USP27 × [47]. In the case of p.Ser404Asn, it was postulated that it works as an alpha helix cap that when mutated, could alter the folding of this local secondary structure. However, these studies were performed with the short isoform of USP27X, which negates the near-entirety of the N-terminus of the protein – a potential confounder when assessing the extent of variant pathogenic severity. Furthermore, these assays were performed with human USP27X transiently transfected in mouse ESCs, potentially obfuscating novel disease phenotypes had the cell model and protein source been of the same species, or a neurodevelopmentally-relevant model.

Just recently, a novel missense USP27X variant was characterized in a three-year-old male p.Thr86Met via trio-whole-exome sequencing, with a phenotype consistent with XLID 105 – notably intellectual disability, speech and motor delay, autistic behaviors, and craniofacial abnormalities (Fig. 2). This rare variant resides in the conserved catalytic domain of USP27X juxtapose to the catalytic cysteine at position 87. ChimeraX analysis of the mutation yielded alternate hydrogen bonding patterns that the Luo research team postulated may yield a destabilized catalytic core. These results were substantiated with functional assays demonstrating easier protein degradation of the p.Thr86Met compared to wild-type (WT) [62]. Another novel characterization made recently involves a case study of a six-year-old boy, where exome sequencing revealed a potential pathologic frameshift USP27X variant p.Leu231Trpfs*13. However, further characterization of this variant remains to be documented [63] (Fig. 2).

As mentioned previously, ATXN7L3 and ENY2 are the key modulators of true DUB activity of the USP enzymes [41]. A co-immunoprecipitation study found that the missense variants p.Gly76Ser and p.Tyr381His led to decreases in USP27X-ATXN7L3 interaction, while p.Tyr144Cys led to an increase. Therefore, it was hypothesized that drastic loss or gain of ATXN7L3 interaction, in addition to compromised catalytic activity of USP27X, could play a role in the pathogenicity of USP27X variants in XLID 105 [47]. Ultimately, a larger sample size, and the use of cellular or animal models to understand the impact of XLID 105 variants in endogenous H2Bub1 levels and in neurodevelopment will be needed to fully understand XLID 105 pathogenesis.

A novel maternally inherited variant of USP51 is associated with a neurodevelopmental disorder

In 2024, a novel USP51 variant was characterized by Garg et al. in a 19-year old biological male (with sex chromosomes XY) with autism spectrum disorder (ASD). Via trio-whole exome sequencing, this maternally inherited variant was termed p.Glu32GlyfsTer25, resulting in a frameshift-mediated truncation of USP51. Symptoms include intellectual disability, epilepsy, and absent speech [64]. Identification of additional individuals harboring USP51 variants with overlapping phenotypes, as well as functional studies investigating the impact of these variants on USP51 activity and downstream cellular functions are warranted to confidently associate USP51 with the observed phenotypes.

De novo variants In ATXN7L3 are associated with a neurodevelopmental disorder

A clinical study identified individuals with neurodevelopmental disorders from nine independent families, harboring heterozygous de novo variants in the ATXN7L3 gene [48]. This condition was named Harel-Tora neurodevelopmental syndrome by OMIM (#621377). Of the five ATXN7L3 variants identified, two of them, p.Arg114Ter and p.Ser112Lysfs12Ter, are predicted to generate truncated versions of the protein and hence result in loss-of-function. Symptoms of the individuals with these variants included global developmental delay, variable cerebral malformations such as leukomalacia or demyelination, craniofacial abnormalities, and hypotonia (Fig. 3). In these truncating variants, the C-terminal half of the protein is lost, including the spinocerebellar ataxia 7 (SCA7) domain which is important for chromatin interaction. Using patient-derived fibroblasts harboring the ATXN7L3 p.Arg114Ter variant, it was demonstrated that the predicted truncated protein is not detectable, and mRNA is degraded by nonsense mediated decay, but these cells express about half of ATXN7L3 protein compared with control, consistent with heterozygosity of this variant. ATXN7L3-variant cells also display elevated total H2Bub1 levels. In case that the p.Ser112Lysfs12Ter truncated protein was expressed, it was postulated that due to the proximity of this C-terminal half of the protein to the zing-finger motif (Znf-Sgf11) which modulates overall SAGA DUB activity, perturbations caused by this de novo variant may yield aberrant folding affecting the ZNF domain and hence, compromised DUB activity [48].

Furthermore, two missense variants ATXN7L3 p.Ser92Arg and p.Leu106Pro lead to single amino acid substitutions within the ZNF domain of the protein while a third missense variant p.Ile71Thr leads to a single amino acid change in the region between the ZNF and ENY2 binding domains of ATXN7L3. Since these variants are within conserved regions of the protein, it is suggested that these missense variants will affect protein function. Symptoms of individuals with these variants are similar to those mentioned previously in addition to presentation of possible convulsions and more severe cerebral malformations such as vermis atrophy or aberrant brain matter proportions [48]. Recently, a novel de novo variant p.Trp79* was identified in a 6.5-year-old boy, leading to premature truncation of the protein. Symptoms included developmental delay, strabismus, polydactyly, hypotonia, dysmorphic features, and abnormal brain MRI [66] (Fig. 3). These findings suggest a role of ATXN7L3 during human development requiring further investigation. Consistent with the phenotypes of humans with Harel-Tora neurodevelopmental syndrome, homozygous deletion of Atxn7l3 in mice resulted in neurologic defects by embryonic day 8.5, with death shortly after. Heterozygous mice, however, were phenotypically normal [52, 67]. Ultimately, direct analysis of the impact of ATXN7L3 missense variants on USP interaction and activation, and global H2Bub1 levels, together with the development of cellular models carrying these variants will be required to fully elucidate the role of ATXN7L3 in neurodevelopment and which steps of this process are affected upon genetic disruption in humans.

Future directions

Here we summarized the literature associated with the role of H2Bub1 DUB complex components in neurodevelopment and human disease. This knowledge is very limited, and a large body of research is still needed to understand how these regulators participate in the development of the human nervous system – especially regarding the direct link between ATXN7L3, USP27X and USP51 neurodevelopmental disorder variants and H2Bub1 regulation, which is still unclear. These efforts will require identification of larger cohorts of patients carrying variants in USP22, USP27X, USP51, ATXN7L3, ENY2 and others but there remains the question of whether any of these genes are essential for life. According to gnomAD v4.1.2, ATXN7L3 and USP22 have a pLi score of 1, ENY2 has a pLI of 0.91, and USP51 has a pLi score of 0.88, while USP27X has a gnomAD v2.1.1 pLi score of 0.92, indicating that these genes are highly constrained and intolerant to loss-of-function genetic variation in humans. This suggests that full gene dosage is important for human physiology. This may explain why variants in ENY2 or USP22 have not been found in patients with neurodevelopmental disorders. However, a more direct investigation of their role in human development will be required to explain this observation.

The current knowledge of the roles of ATXN7L3-dependent DUB complex components in neural development is still weak and is based on preliminary observations. A systematic analysis of the roles and downstream mechanisms orchestrated by these genes either H2Bub1-dependent or independent will be required for a confident association with neurodevelopment. For this, detailed study of their expression patterns, identification of the relevant cell types involved in their functions, generation of cellular or animal models of their depletion and systematic research of their role in brain development will be required.

It is unclear if H2Bub1 is regulated by ATXN7L3-dependent DUB complexes in human neural cells. Given the exquisite tissue specificity of DUB-substrate partnerships, this confirmation is required to fully define the role of H2Bub1 deubiquitylation in human neural development. This will be enabled by human induced pluripotent stem cell (iPSC) culture and differentiation with gene editing techniques. Engineering of knockout iPSCs lacking ATXN7L3-dependent DUB components or knockin iPSCs carrying gene variants found in humans will be key models to study their functional impact in the differentiation and function of individual neural cell types or in tissue-like differentiation models such as organoids or assembloids. The identification of the genes and transcriptional programs regulated by each component will require chromatin and transcriptional profiling techniques such as H2Bub1 chromatin immunoprecipitation (ChIP)-SEQ or CUT&Tag, combined with RNA-SEQ. Together, these approached will enable identifying the developmental programs and cellular processes regulated by H2Bub1 to better understand how their disruption drives neurodevelopmental disorders.

There remains the possibility that USP22, USP27X and USP51 target substrates beyond histone H2B in neural cells. Identification of these additional neural-specific substrates will be enabled by state-of-the-art techniques such as quantitative proteomics, genetic screens with CRISPR/Cas9 and in vitro ubiquitylation assays. The same applies to known USP22 substrates such as MYC, Androgen receptor, HES1, Xeroderma Pigmentosum group C protein or USP27X substrates such as cGAS, CBX2, Cyclin D1, cFLIPL, Cyclin E, SNAIL, BIM, RIG-I, HES1 and SETD3 that have been discovered in non-neural cell types [49, 52, 55, 68–75].

Key open questions are how do USP27X, USP51 and ATXN7L3 variants affect H2Bub1 levels in neural cells, if this leads to alterations in downstream gene expression and hence, yields neurodevelopmental disorder manifestation. Future studies aiming to answer these questions will aid in defining therapeutic targets and development of disease-modifying therapies such as enzyme replacement or small-molecule intervention. In summary, the existence of developmental disorders driven by disruption of ATXN7L3-dependent DUB complex components strongly suggests a role of H2Bub1 modification and its regulation in human neural development. However, extensive research is needed to definitively establish this connection.

References

1. Vissers LE Gilissen C Veltman JA Genetic studies in intellectual disability and related disorders Nat Rev Genet 2016 17 1 9 18 10.1038/nrg3999 26503795 Vissers LE, Gilissen C, Veltman JA (2016) Genetic studies in intellectual disability and related disorders. Nat Rev Genet 17(1):9–1810.1038/nrg3999 26503795

2. Schwartz CE Louie RJ Toutain A Skinner C Friez MJ Stevenson RE X-Linked intellectual disability update 2022 Am J Med Genet A 2023 191 1 144 159 36300573 10.1002/ajmg.a.63008 Schwartz CE, Louie RJ, Toutain A, Skinner C, Friez MJ, Stevenson RE (2023) X-Linked intellectual disability update 2022. Am J Med Genet A 191(1):144–15910.1002/ajmg.a.63008 36300573

3. Leonard H Wen X The epidemiology of mental retardation: challenges and opportunities in the new millennium Ment Retard Dev Disabil Res Rev 2002 8 3 117 134 12216056 10.1002/mrdd.10031 Leonard H, Wen X (2002) The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 8(3):117–13410.1002/mrdd.10031 12216056

4. Maulik PK Mascarenhas MN Mathers CD Dua T Saxena S Prevalence of intellectual disability: a meta-analysis of population-based studies Res Dev Disabil 2011 32 2 419 436 21236634 10.1016/j.ridd.2010.12.018 Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S (2011) Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 32(2):419–43610.1016/j.ridd.2010.12.018 21236634

5. Picker JD Walsh CA New innovations: therapeutic opportunities for intellectual disabilities Ann Neurol 2013 74 3 382 390 24038210 10.1002/ana.24002 Picker JD, Walsh CA (2013) New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol 74(3):382–39010.1002/ana.24002 PMC3876407 24038210

6. Yau R Rape M The increasing complexity of the ubiquitin code Nat Cell Biol 2016 18 6 579 586 10.1038/ncb3358 27230526 Yau R, Rape M (2016) The increasing complexity of the ubiquitin code. Nat Cell Biol 18(6):579–58610.1038/ncb3358 27230526

7. Hershko A Ciechanover A Varshavsky A Basic Medical Research Award. The ubiquitin system Nat Med 2000 6 10 1073 1081 10.1038/80384 11017125 Hershko A, Ciechanover A, Varshavsky A (2000) Basic Medical Research Award. The ubiquitin system. Nat Med 6(10):1073–108110.1038/80384 11017125

8. Petroski MD The ubiquitin system, disease, and drug discovery BMC Biochem 2008 9 Suppl 1 S7 10.1186/1471-2091-9-S1-S7 19007437 Petroski MD (2008) The ubiquitin system, disease, and drug discovery. BMC Biochem 9(Suppl 1):S710.1186/1471-2091-9-S1-S7 PMC2582801 19007437

9. Pickart CM Mechanisms underlying ubiquitination Annu Rev Biochem 2001 70 503 533 11395416 10.1146/annurev.biochem.70.1.503 Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503–53310.1146/annurev.biochem.70.1.503 11395416

10. Komander D Clague MJ Urbe S Breaking the chains: structure and function of the deubiquitinases Nat Rev Mol Cell Biol 2009 10 8 550 63 10.1038/nrm2731 19626045 Komander D, Clague MJ, Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10(8):550–6310.1038/nrm2731 19626045

11. Ebstein F Kury S Papendorf JJ Kruger E Neurodevelopmental disorders (NDD) caused by genomic alterations of the ubiquitin-proteasome system (UPS): the possible contribution of immune dysregulation to disease pathogenesis Front Mol Neurosci 2021 14 733012 34566579 10.3389/fnmol.2021.733012 Ebstein F, Kury S, Papendorf JJ, Kruger E (2021) Neurodevelopmental disorders (NDD) caused by genomic alterations of the ubiquitin-proteasome system (UPS): the possible contribution of immune dysregulation to disease pathogenesis. Front Mol Neurosci 14:73301210.3389/fnmol.2021.733012 PMC8455891 34566579

12. Hu H Haas SA Chelly J Van Esch H Raynaud M de Brouwer AP X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes Mol Psychiatry 2016 21 1 133 148 10.1038/mp.2014.193 25644381 PMC5414091 Hu H, Haas SA, Chelly J, Van Esch H, Raynaud M, de Brouwer AP et al (2016) X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. Mol Psychiatry 21(1):133–14810.1038/mp.2014.193 PMC5414091 25644381

13. Santiago-Sim T Burrage LC Ebstein F Tokita MJ Miller M Bi W Biallelic Variants in OTUD6B Cause an Intellectual Disability Syndrome Associated with Seizures and Dysmorphic Features Am J Hum Genet 2017 100 4 676 688 28343629 10.1016/j.ajhg.2017.03.001 Santiago-Sim T, Burrage LC, Ebstein F, Tokita MJ, Miller M, Bi W et al (2017) Biallelic Variants in OTUD6B Cause an Intellectual Disability Syndrome Associated with Seizures and Dysmorphic Features. Am J Hum Genet 100(4):676–68810.1016/j.ajhg.2017.03.001 PMC5384096 28343629

14. Johnson BV Kumar R Oishi S Alexander S Kasherman M Vega MS Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling Biol Psychiatry 2020 87 2 100 112 31443933 10.1016/j.biopsych.2019.05.028 PMC6925349 Johnson BV, Kumar R, Oishi S, Alexander S, Kasherman M, Vega MS et al (2020) Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling. Biol Psychiatry 87(2):100–11210.1016/j.biopsych.2019.05.028 PMC6925349 31443933

15. Beck DB Basar MA Asmar AJ Thompson JJ Oda H Uehara DT Linkage-specific deubiquitylation by OTUD5 defines an embryonic pathway intolerant to genomic variation Sci Adv 2021 10.1126/sciadv.abe2116 33523931 PMC7817106 Beck DB, Basar MA, Asmar AJ, Thompson JJ, Oda H, Uehara DT et al (2021) Linkage-specific deubiquitylation by OTUD5 defines an embryonic pathway intolerant to genomic variation. Sci Adv. 10.1126/sciadv.abe2116 PMC7817106 33523931

16. Minsky N Shema E Field Y Schuster M Segal E Oren M Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells Nat Cell Biol 2008 10 4 483 488 10.1038/ncb1712 18344985 Minsky N, Shema E, Field Y, Schuster M, Segal E, Oren M (2008) Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol 10(4):483–48810.1038/ncb1712 18344985

17. Smith E Shilatifard A The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes Mol Cell 2010 40 5 689 701 21145479 10.1016/j.molcel.2010.11.031 Smith E, Shilatifard A (2010) The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell 40(5):689–70110.1016/j.molcel.2010.11.031 PMC3037032 21145479

18. Henry KW Wyce A Lo WS Duggan LJ Emre NC Kao CF Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8 Genes Dev 2003 17 21 2648 2663 14563679 10.1101/gad.1144003 Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, Kao CF et al (2003) Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 17(21):2648–266310.1101/gad.1144003 PMC280615 14563679

19. Bonnet J Wang CY Baptista T Vincent SD Hsiao WC Stierle M The SAGA coactivator complex acts on the whole transcribed genome and is required for RNA polymerase II transcription Genes Dev 2014 28 18 1999 2012 25228644 10.1101/gad.250225.114 Bonnet J, Wang CY, Baptista T, Vincent SD, Hsiao WC, Stierle M et al (2014) The SAGA coactivator complex acts on the whole transcribed genome and is required for RNA polymerase II transcription. Genes Dev 28(18):1999–201210.1101/gad.250225.114 PMC4173158 25228644

20. Fuchs G Hollander D Voichek Y Ast G Oren M Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate Genome Res 2014 24 10 1572 1583 25049226 10.1101/gr.176487.114 Fuchs G, Hollander D, Voichek Y, Ast G, Oren M (2014) Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate. Genome Res 24(10):1572–158310.1101/gr.176487.114 PMC4199367 25049226

21. Weake VM Workman JL Histone ubiquitination: triggering gene activity Mol Cell 2008 29 6 653 663 18374642 10.1016/j.molcel.2008.02.014 Weake VM, Workman JL (2008) Histone ubiquitination: triggering gene activity. Mol Cell 29(6):653–66310.1016/j.molcel.2008.02.014 18374642

22. Tarcic O Pateras IS Cooks T Shema E Kanterman J Ashkenazi H RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer Cell Rep 2016 14 6 1462 1476 26854224 10.1016/j.celrep.2016.01.020 Tarcic O, Pateras IS, Cooks T, Shema E, Kanterman J, Ashkenazi H et al (2016) RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep 14(6):1462–147610.1016/j.celrep.2016.01.020 PMC4761112 26854224

23. Jaaskelainen T Makkonen H Visakorpi T Kim J Roeder RG Palvimo JJ Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth Mol Cell Endocrinol 2012 350 1 87 98 22155569 10.1016/j.mce.2011.11.025 Jaaskelainen T, Makkonen H, Visakorpi T, Kim J, Roeder RG, Palvimo JJ (2012) Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. Mol Cell Endocrinol 350(1):87–9810.1016/j.mce.2011.11.025 22155569

24. So CC Ramachandran S Martin A E3 ubiquitin ligases RNF20 and RNF40 are required for double-stranded break (DSB) repair: evidence for monoubiquitination of histone H2B lysine 120 as a novel axis of DSB signaling and repair Mol Cell Biol 2019 10.1128/MCB.00488-18 30692271 PMC6447412 So CC, Ramachandran S, Martin A (2019) E3 ubiquitin ligases RNF20 and RNF40 are required for double-stranded break (DSB) repair: evidence for monoubiquitination of histone H2B lysine 120 as a novel axis of DSB signaling and repair. Mol Cell Biol. 10.1128/MCB.00488-18 PMC6447412 30692271

25. Shiloh Y Shema E Moyal L Oren M RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response FEBS Lett 2011 585 18 2795 2802 21827756 10.1016/j.febslet.2011.07.034 Shiloh Y, Shema E, Moyal L, Oren M (2011) RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response. FEBS Lett 585(18):2795–280210.1016/j.febslet.2011.07.034 21827756

26. Chernikova SB Razorenova OV Higgins JP Sishc BJ Nicolau M Dorth JA Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability Cancer Res 2012 72 8 2111 2119 22354749 10.1158/0008-5472.CAN-11-2209 Chernikova SB, Razorenova OV, Higgins JP, Sishc BJ, Nicolau M, Dorth JA et al (2012) Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability. Cancer Res 72(8):2111–211910.1158/0008-5472.CAN-11-2209 PMC3328627 22354749

27. Zhang K Wang J Tong TR Wu X Nelson R Yuan YC Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma Int J Cancer 2017 141 4 766 777 28481029 10.1002/ijc.30769 Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC et al (2017) Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer 141(4):766–77710.1002/ijc.30769 PMC5527746 28481029

28. Li Y Ma T Jiang J Hahn M Yin Y The dynamics and functional mechanisms of H2B mono-ubiquitination Crop Health 2024 2 1 1 10.1007/s44297-023-00022-9 41649658 Li Y, Ma T, Jiang J, Hahn M, Yin Y (2024) The dynamics and functional mechanisms of H2B mono-ubiquitination. Crop Health 2(1):110.1007/s44297-023-00022-9 PMC12825983 41649658

29. Barrios R Vega M Gracia-Domingo R Boronat S Garcia-Santamarina S Tanny JC Distinct roles of histone H2B ubiquitination at promoters and coding regions of Pol II-transcribed stress genes Genome Biol 2025 26 1 419 10.1186/s13059-025-03891-1 41366798 Barrios R, Vega M, Gracia-Domingo R, Boronat S, Garcia-Santamarina S, Tanny JC et al (2025) Distinct roles of histone H2B ubiquitination at promoters and coding regions of Pol II-transcribed stress genes. Genome Biol 26(1):41910.1186/s13059-025-03891-1 PMC12687531 41366798

30. Luo A Kong J Chen J Xiao X Lan J Li X H2B ubiquitination recruits FACT to maintain a stable altered nucleosome state for transcriptional activation Nat Commun 2023 14 1 741 10.1038/s41467-023-36467-3 36765085 Luo A, Kong J, Chen J, Xiao X, Lan J, Li X et al (2023) H2B ubiquitination recruits FACT to maintain a stable altered nucleosome state for transcriptional activation. Nat Commun 14(1):74110.1038/s41467-023-36467-3 PMC9918737 36765085

31. Chandrasekharan MB Huang F Sun ZW Ubiquitination of histone H2B regulates chromatin dynamics by enhancing nucleosome stability Proc Natl Acad Sci U S A 2009 106 39 16686 16691 19805358 10.1073/pnas.0907862106 Chandrasekharan MB, Huang F, Sun ZW (2009) Ubiquitination of histone H2B regulates chromatin dynamics by enhancing nucleosome stability. Proc Natl Acad Sci U S A 106(39):16686–1669110.1073/pnas.0907862106 PMC2757834 19805358

32. Lang G Bonnet J Umlauf D Karmodiya K Koffler J Stierle M The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements Mol Cell Biol 2011 31 18 3734 3744 21746879 10.1128/MCB.05231-11 Lang G, Bonnet J, Umlauf D, Karmodiya K, Koffler J, Stierle M et al (2011) The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol 31(18):3734–374410.1128/MCB.05231-11 PMC3165722 21746879

33. Mohan RD Dialynas G Weake VM Liu J Martin-Brown S Florens L Loss of Drosophila Ataxin-7, a SAGA subunit, reduces H2B ubiquitination and leads to neural and retinal degeneration Genes Dev 2014 28 3 259 272 24493646 10.1101/gad.225151.113 Mohan RD, Dialynas G, Weake VM, Liu J, Martin-Brown S, Florens L et al (2014) Loss of Drosophila Ataxin-7, a SAGA subunit, reduces H2B ubiquitination and leads to neural and retinal degeneration. Genes Dev 28(3):259–27210.1101/gad.225151.113 PMC3923968 24493646

34. Kohler A Schneider M Cabal GG Nehrbass U Hurt E Yeast Ataxin-7 links histone deubiquitination with gene gating and mRNA export Nat Cell Biol 2008 10 6 707 715 10.1038/ncb1733 18488019 Kohler A, Schneider M, Cabal GG, Nehrbass U, Hurt E (2008) Yeast Ataxin-7 links histone deubiquitination with gene gating and mRNA export. Nat Cell Biol 10(6):707–71510.1038/ncb1733 18488019

35. Kohler A Zimmerman E Schneider M Hurt E Zheng N Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module Cell 2010 141 4 606 617 20434206 10.1016/j.cell.2010.04.026 Kohler A, Zimmerman E, Schneider M, Hurt E, Zheng N (2010) Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module. Cell 141(4):606–61710.1016/j.cell.2010.04.026 PMC2901531 20434206

36. Lee KK Sardiu ME Swanson SK Gilmore JM Torok M Grant PA Combinatorial depletion analysis to assemble the network architecture of the SAGA and ADA chromatin remodeling complexes Mol Syst Biol 2011 7 503 10.1038/msb.2011.40 21734642 Lee KK, Sardiu ME, Swanson SK, Gilmore JM, Torok M, Grant PA et al (2011) Combinatorial depletion analysis to assemble the network architecture of the SAGA and ADA chromatin remodeling complexes. Mol Syst Biol 7:50310.1038/msb.2011.40 PMC3159981 21734642

37. Samara NL Datta AB Berndsen CE Zhang X Yao T Cohen RE Structural insights into the assembly and function of the SAGA deubiquitinating module Science 2010 328 5981 1025 1029 20395473 10.1126/science.1190049 Samara NL, Datta AB, Berndsen CE, Zhang X, Yao T, Cohen RE et al (2010) Structural insights into the assembly and function of the SAGA deubiquitinating module. Science 328(5981):1025–102910.1126/science.1190049 PMC4220450 20395473

38. Zhang XY Varthi M Sykes SM Phillips C Warzecha C Zhu W The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression Mol Cell 2008 29 1 102 111 18206973 10.1016/j.molcel.2007.12.015 Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W et al (2008) The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29(1):102–11110.1016/j.molcel.2007.12.015 PMC2254522 18206973

39. Zhao Y Lang G Ito S Bonnet J Metzger E Sawatsubashi S A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing Mol Cell 2008 29 1 92 101 18206972 10.1016/j.molcel.2007.12.011 Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S et al (2008) A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 29(1):92–10110.1016/j.molcel.2007.12.011 18206972

40. Lan X Koutelou E Schibler AC Chen YC Grant PA Dent SY Poly(Q) Expansions in ATXN7 Affect Solubility but Not Activity of the SAGA Deubiquitinating Module Mol Cell Biol 2015 35 10 1777 1787 25755283 10.1128/MCB.01454-14 Lan X, Koutelou E, Schibler AC, Chen YC, Grant PA, Dent SY (2015) Poly(Q) Expansions in ATXN7 Affect Solubility but Not Activity of the SAGA Deubiquitinating Module. Mol Cell Biol 35(10):1777–178710.1128/MCB.01454-14 PMC4405643 25755283

41. Atanassov BS Mohan RD Lan X Kuang X Lu Y Lin K ATXN7L3 and ENY2 Coordinate Activity of Multiple H2B Deubiquitinases Important for Cellular Proliferation and Tumor Growth Mol Cell 2016 62 4 558 571 27132940 10.1016/j.molcel.2016.03.030 Atanassov BS, Mohan RD, Lan X, Kuang X, Lu Y, Lin K et al (2016) ATXN7L3 and ENY2 Coordinate Activity of Multiple H2B Deubiquitinases Important for Cellular Proliferation and Tumor Growth. Mol Cell 62(4):558–57110.1016/j.molcel.2016.03.030 PMC4874879 27132940

42. Kim DH Kim SL Singh V Ramakrishna S Usp7 Regulates Glial Lineage Cell-Specific Transcription Factors by Modulating Histone H2B Monoubiquitination Int J Stem Cells 2024 17 4 427 436 38952059 10.15283/ijsc23202 Kim DH, Kim SL, Singh V, Ramakrishna S (2024) Usp7 Regulates Glial Lineage Cell-Specific Transcription Factors by Modulating Histone H2B Monoubiquitination. Int J Stem Cells 17(4):427–43610.15283/ijsc23202 PMC11612222 38952059

43. Nicassio F Corrado N Vissers JH Areces LB Bergink S Marteijn JA Human USP3 is a chromatin modifier required for S phase progression and genome stability Curr Biol 2007 17 22 1972 1977 17980597 10.1016/j.cub.2007.10.034 Nicassio F, Corrado N, Vissers JH, Areces LB, Bergink S, Marteijn JA et al (2007) Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr Biol 17(22):1972–197710.1016/j.cub.2007.10.034 17980597

44. Su D Wang W Hou Y Wang L Yi X Cao C Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis Nucleic Acids Res 2021 49 8 4421 4440 33849069 10.1093/nar/gkab209 Su D, Wang W, Hou Y, Wang L, Yi X, Cao C et al (2021) Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis. Nucleic Acids Res 49(8):4421–444010.1093/nar/gkab209 PMC8096222 33849069

45. van der Knaap JA Kumar BR Moshkin YM Langenberg K Krijgsveld J Heck AJ GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7 Mol Cell 2005 17 5 695 707 15749019 10.1016/j.molcel.2005.02.013 van der Knaap JA, Kumar BR, Moshkin YM, Langenberg K, Krijgsveld J, Heck AJ et al (2005) GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Mol Cell 17(5):695–70710.1016/j.molcel.2005.02.013 15749019

46. Joo HY Jones A Yang C Zhai L Smith AD Zhang Z Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46 J Biol Chem 2011 286 9 7190 201 21183687 10.1074/jbc.M110.158311 PMC3044976 Joo HY, Jones A, Yang C, Zhai L, Smith AD, Zhang Z et al (2011) Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46. J Biol Chem 286(9):7190–20110.1074/jbc.M110.158311 PMC3044976 21183687

47. Koch I Slovik M Zhang Y Liu B Rennie M Konz E USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms Life Sci Alliance 2024 10.26508/lsa.202302258 38182161 Koch I, Slovik M, Zhang Y, Liu B, Rennie M, Konz E et al (2024) USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms. Life Sci Alliance. 10.26508/lsa.202302258 PMC10770416 38182161

48. Harel T Spicher C Scheer E Buchan JG Cech J Folland C De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features Brain 2024 147 8 2732 2744 38753057 10.1093/brain/awae160 Harel T, Spicher C, Scheer E, Buchan JG, Cech J, Folland C et al (2024) De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features. Brain 147(8):2732–274410.1093/brain/awae160 38753057

49. Dold MN Ng X Alber C Gentle IE Hacker G Weber A The deubiquitinase Usp27x as a novel regulator of cFLIP(L) protein expression and sensitizer to death-receptor-induced apoptosis Apoptosis 2022 27 1–2 112 132 10.1007/s10495-021-01706-9 35044632 Dold MN, Ng X, Alber C, Gentle IE, Hacker G, Weber A (2022) The deubiquitinase Usp27x as a novel regulator of cFLIP(L) protein expression and sensitizer to death-receptor-induced apoptosis. Apoptosis 27(1–2):112–13210.1007/s10495-021-01706-9 PMC8863773 35044632

50. Liang Q Xia W Li W Jiao J RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain Cell Death Differ 2018 25 2 294 306 10.1038/cdd.2017.157 28984873 PMC5762844 Liang Q, Xia W, Li W, Jiao J (2018) RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain. Cell Death Differ 25(2):294–30610.1038/cdd.2017.157 PMC5762844 28984873

51. Wust HM Wegener A Frob F Hartwig AC Wegwitz F Kari V Egr2-guided histone H2B monoubiquitination is required for peripheral nervous system myelination Nucleic Acids Res 2020 48 16 8959 8976 32672815 10.1093/nar/gkaa606 Wust HM, Wegener A, Frob F, Hartwig AC, Wegwitz F, Kari V et al (2020) Egr2-guided histone H2B monoubiquitination is required for peripheral nervous system myelination. Nucleic Acids Res 48(16):8959–897610.1093/nar/gkaa606 PMC7498331 32672815

52. Wang F El-Saafin F Ye T Stierle M Negroni L Durik M Histone H2Bub1 deubiquitylation is essential for mouse development, but does not regulate global RNA polymerase II transcription Cell Death Differ 2021 28 8 2385 2403 10.1038/s41418-021-00759-2 33731875 Wang F, El-Saafin F, Ye T, Stierle M, Negroni L, Durik M et al (2021) Histone H2Bub1 deubiquitylation is essential for mouse development, but does not regulate global RNA polymerase II transcription. Cell Death Differ 28(8):2385–240310.1038/s41418-021-00759-2 PMC8329007 33731875

53. Lin Z Yang H Kong Q Li J Lee SM Gao B USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development Mol Cell 2012 46 4 484 494 22542455 10.1016/j.molcel.2012.03.024 Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B et al (2012) USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46(4):484–49410.1016/j.molcel.2012.03.024 22542455

54. MGI I (2018) MGI Load of Endonuclease-Mediated Alleles (CRISPR) from the International Mouse Phenotyping Consortium (IMPC). Database Release

55. Kobayashi T Iwamoto Y Takashima K Isomura A Kosodo Y Kawakami K Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation FEBS J 2015 282 13 2411 23 25846153 10.1111/febs.13290 Kobayashi T, Iwamoto Y, Takashima K, Isomura A, Kosodo Y, Kawakami K et al (2015) Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation. FEBS J 282(13):2411–2310.1111/febs.13290 25846153

56. Zhang Z Li J Wang B Hou C Liu Q Wang W Ubiquitin-Specific Protease 22 Promotes Neural Stem Cells Stemness Maintenance and Adult Hippocampal Neurogenesis, Contributing to Cognitive Recovery Following Traumatic Brain Injury Neuroscience 2022 496 219 229 35700816 10.1016/j.neuroscience.2022.06.014 Zhang Z, Li J, Wang B, Hou C, Liu Q, Wang W et al (2022) Ubiquitin-Specific Protease 22 Promotes Neural Stem Cells Stemness Maintenance and Adult Hippocampal Neurogenesis, Contributing to Cognitive Recovery Following Traumatic Brain Injury. Neuroscience 496:219–22910.1016/j.neuroscience.2022.06.014 35700816

57. Thomson M Liu SJ Zou LN Smith Z Meissner A Ramanathan S Pluripotency factors in embryonic stem cells regulate differentiation into germ layers Cell 2011 145 6 875 889 21663792 10.1016/j.cell.2011.05.017 Thomson M, Liu SJ, Zou LN, Smith Z, Meissner A, Ramanathan S (2011) Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell 145(6):875–88910.1016/j.cell.2011.05.017 PMC5603300 21663792

58. Wang Z Oron E Nelson B Razis S Ivanova N Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells Cell Stem Cell 2012 10 4 440 454 22482508 10.1016/j.stem.2012.02.016 Wang Z, Oron E, Nelson B, Razis S, Ivanova N (2012) Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 10(4):440–45410.1016/j.stem.2012.02.016 22482508

59. Sussman RT Stanek TJ Esteso P Gearhart JD Knudsen KE McMahon SB The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2) J Biol Chem 2013 288 33 24234 24246 23760504 10.1074/jbc.M113.469783 Sussman RT, Stanek TJ, Esteso P, Gearhart JD, Knudsen KE, McMahon SB (2013) The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). J Biol Chem 288(33):24234–2424610.1074/jbc.M113.469783 PMC3745368 23760504

60. Ekkebus R van Kasteren SI Kulathu Y Scholten A Berlin I Geurink PP On terminal alkynes that can react with active-site cysteine nucleophiles in proteases J Am Chem Soc 2013 135 8 2867 2870 23387960 10.1021/ja309802n Ekkebus R, van Kasteren SI, Kulathu Y, Scholten A, Berlin I, Geurink PP et al (2013) On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc 135(8):2867–287010.1021/ja309802n PMC3585465 23387960

61. Ekkebus R Flierman D Geurink PP Ovaa H Catching a DUB in the act: novel ubiquitin-based active site directed probes Curr Opin Chem Biol 2014 23 63 70 25461387 10.1016/j.cbpa.2014.10.005 Ekkebus R, Flierman D, Geurink PP, Ovaa H (2014) Catching a DUB in the act: novel ubiquitin-based active site directed probes. Curr Opin Chem Biol 23:63–7010.1016/j.cbpa.2014.10.005 PMC7185813 25461387

62. Luo S Zhang M Zhang X Huang Y Tan L Zhao P A novel USP27X missense variant identified in an individual with intellectual disability J Hum Genet 2025 70 9 489 494 10.1038/s10038-025-01359-5 40596734 Luo S, Zhang M, Zhang X, Huang Y, Tan L, Zhao P et al (2025) A novel USP27X missense variant identified in an individual with intellectual disability. J Hum Genet 70(9):489–49410.1038/s10038-025-01359-5 40596734

63. Maria Dolores-Sanchez C Doval-Calvo D Ballesta-Martinez MJ Sanchez-Soler MJ [Two new cases of X-linked intellectual developmental disorder-105 linked to a previously unreported pathogenic variant in the USP27X gene] Rev Neurol 2024 79 3 95 97 39007861 10.33588/rn.7903.2024097 Maria Dolores-Sanchez C, Doval-Calvo D, Ballesta-Martinez MJ, Sanchez-Soler MJ (2024) [Two new cases of X-linked intellectual developmental disorder-105 linked to a previously unreported pathogenic variant in the USP27X gene]. Rev Neurol 79(3):95–9710.33588/rn.7903.2024097 PMC11469094 39007861

64. Garg R, Pinard A, Wallerstein R (2024) A novel USP51 variant in a patient with autism spectrum disorder and epilepsy. Egypt J Med Hum Genet

65. Cornelio-Parra DV Goswami R Costanzo K Morales-Sosa P Mohan RD Function and regulation of the Spt-Ada-Gcn5-Acetyltransferase (SAGA) deubiquitinase module Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2021 1864 2 194630 32911111 10.1016/j.bbagrm.2020.194630 Cornelio-Parra DV, Goswami R, Costanzo K, Morales-Sosa P, Mohan RD (2021) Function and regulation of the Spt-Ada-Gcn5-Acetyltransferase (SAGA) deubiquitinase module. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1864(2):19463010.1016/j.bbagrm.2020.194630 32911111

66. Umair M Ahmed Z Mahmood A Khan H Khan MJ Ali RH A novel ATXN7L3 de novo variant underlies Harel-Tora neurodevelopmental syndrome (HATONS) with pre-axial polydactyly Clin Genet 2026 10.1111/cge.70156 41760364 Umair M, Ahmed Z, Mahmood A, Khan H, Khan MJ, Ali RH (2026) A novel ATXN7L3 de novo variant underlies Harel-Tora neurodevelopmental syndrome (HATONS) with pre-axial polydactyly. Clin Genet. 10.1111/cge.70156 41760364

67. El-Saafin F Devys D Johnsen SA Vincent SD Tora L SAGA-dependent histone H2Bub1 deubiquitination is essential for cellular ubiquitin balance during embryonic development Int J Mol Sci 2022 10.3390/ijms23137459 35806465 El-Saafin F, Devys D, Johnsen SA, Vincent SD, Tora L (2022) SAGA-dependent histone H2Bub1 deubiquitination is essential for cellular ubiquitin balance during embryonic development. Int J Mol Sci. 10.3390/ijms23137459 PMC9267394 35806465

68. Guo Y Jiang F Kong L Li B Yang Y Zhang L Cutting Edge: USP27X Deubiquitinates and Stabilizes the DNA Sensor cGAS to Regulate Cytosolic DNA-Mediated Signaling J Immunol 2019 203 8 2049 2054 31534008 10.4049/jimmunol.1900514 Guo Y, Jiang F, Kong L, Li B, Yang Y, Zhang L et al (2019) Cutting Edge: USP27X Deubiquitinates and Stabilizes the DNA Sensor cGAS to Regulate Cytosolic DNA-Mediated Signaling. J Immunol 203(8):2049–205410.4049/jimmunol.1900514 31534008

69. Xing Y Ba-Tu J Dong C Cao X Li B Jia X Phosphorylation of USP27X by GSK3beta maintains the stability and oncogenic functions of CBX2 Cell Death Dis 2023 14 11 782 38030604 10.1038/s41419-023-06304-y Xing Y, Ba-Tu J, Dong C, Cao X, Li B, Jia X et al (2023) Phosphorylation of USP27X by GSK3beta maintains the stability and oncogenic functions of CBX2. Cell Death Dis 14(11):78210.1038/s41419-023-06304-y PMC10687032 38030604

70. Alam S Zunic A Venkat S Feigin ME Atanassov BS Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth Mol Cancer Res 2022 20 12 1751 1762 36001804 10.1158/1541-7786.MCR-22-0259 Alam S, Zunic A, Venkat S, Feigin ME, Atanassov BS (2022) Regulation of Cyclin D1 Degradation by Ubiquitin-Specific Protease 27X Is Critical for Cancer Cell Proliferation and Tumor Growth. Mol Cancer Res 20(12):1751–176210.1158/1541-7786.MCR-22-0259 PMC9722596 36001804

71. Dong L Yu L Bai C Liu L Long H Shi L USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis Oncogene 2018 37 20 2702 2713 10.1038/s41388-018-0137-z 29497124 Dong L, Yu L, Bai C, Liu L, Long H, Shi L et al (2018) USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis. Oncogene 37(20):2702–271310.1038/s41388-018-0137-z PMC5955865 29497124

72. Lambies G Miceli M Martinez-Guillamon C Olivera-Salguero R Pena R Frias CP TGFbeta-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1 Cancer Res 2019 79 1 33 46 30341066 10.1158/0008-5472.CAN-18-0753 PMC9386731 Lambies G, Miceli M, Martinez-Guillamon C, Olivera-Salguero R, Pena R, Frias CP et al (2019) TGFbeta-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. Cancer Res 79(1):33–4610.1158/0008-5472.CAN-18-0753 PMC9386731 30341066

73. Weber A Heinlein M Dengjel J Alber C Singh PK Hacker G The deubiquitinase Usp27x stabilizes the BH3-only protein Bim and enhances apoptosis EMBO Rep 2016 17 5 724 738 10.15252/embr.201541392 27013495 Weber A, Heinlein M, Dengjel J, Alber C, Singh PK, Hacker G (2016) The deubiquitinase Usp27x stabilizes the BH3-only protein Bim and enhances apoptosis. EMBO Rep 17(5):724–73810.15252/embr.201541392 PMC5341510 27013495

74. Tao X Chu B Xin D Li L Sun Q USP27X negatively regulates antiviral signaling by deubiquitinating RIG-I PLoS Pathog 2020 16 2 e1008293 32027733 10.1371/journal.ppat.1008293 Tao X, Chu B, Xin D, Li L, Sun Q (2020) USP27X negatively regulates antiviral signaling by deubiquitinating RIG-I. PLoS Pathog 16(2):e100829310.1371/journal.ppat.1008293 PMC7029883 32027733

75. Zou T Wang Y Dong L Che T Zhao H Yan X Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression Cell Mol Life Sci 2022 79 1 70 10.1007/s00018-021-04118-9 35018513 Zou T, Wang Y, Dong L, Che T, Zhao H, Yan X et al (2022) Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression. Cell Mol Life Sci 79(1):7010.1007/s00018-021-04118-9 PMC8752572 35018513

76. A, A. (2026). Anand et al 2026 Fig. 1. Created in BioRender. https://BioRender.com/ot9dkd8

77. A, A. (2026). X-linked intellectual disorder 105 is associated with pathogenic variants in the USP27X gene. Created in BioRender. https://BioRender.com/061pjyt

78. A, A. (2026). Harel-Tora neurodevelopmental disorder is associated with heterozygous de novo variants in the ATXN7L3 gene.. Created in BioRender. https://BioRender.com/vy6kawz

Come citare questo studio

Abhinav Anand, Francisco Bustos. (2026). Is histone H2B deubiquitylation via ATXN7L3-dependent enzymes a new mechanism disrupted in neurodevelopmental disorders?. Neurogenetics. DOI: 10.1007/s10048-026-00954-8

Consulta la pubblicazione originale ↗